Skip to main content


Presenter: Rene Westhovens, Katholieke Universiteit Leuven, Belgium.

Saturday 15 June: 08:00–09:00 (Abstract LB003)

The aim of FINCH 3 is to evaluate the efficacy of filgotinib in combination with methotrexate compared with methotrexate alone in methotrexate-naïve adult patients with rheumatoid arthritis (RA). The 1252 enrolled participants were randomly assigned to receive filgotinib, methotrexate, or a combination of both treatments for 1 year, and the primary outcome is the proportion of participants with an ACR20 response at week 24.

More on this trial